An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
Conditions: Non-Small Cell Lung Cancer; Non-Small-Cell Lung Carcinoma; Circulating Tumor DNA Interventions: Biological: Nivolumab; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Docetaxel; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin; Drug: Paclitaxel; Other: Observation Sponsor: Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Carcinoma | Docetaxel | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study | Taxotere